Evidence Connections

Follow the evidence beyond the paper.

Follow source-linked research projects, organizations, FDA application actions, compound targets and genetic studies.

Explore relationships stated by the original sources. Each number opens its exact collection—not a count of extra papers or proven treatments.

ChEMBL compound–target relationships

5

Indexed connections · inspect this exact collection

Compound ↔ targetDate not supplied

EVEROLIMUS

INHIBITOR · CHEMBL1902

A compound–target relationship reported by ChEMBL. It does not establish clinical benefit, safety or an effect on lifespan.

Source: ChEMBL, CC BY-SA 3.0. Selected structured fields; adaptations remain CC BY-SA 3.0. ChEMBL publication: https://europepmc.org/article/MED/30398643 . Licence

Inspect the source record →Inspect the target →
Compound ↔ targetDate not supplied

POZELIMAB

INHIBITOR · CHEMBL2364163

A compound–target relationship reported by ChEMBL. It does not establish clinical benefit, safety or an effect on lifespan.

Source: ChEMBL, CC BY-SA 3.0. Selected structured fields; adaptations remain CC BY-SA 3.0. ChEMBL publication: https://europepmc.org/article/MED/30398643 . Licence

Inspect the source record →Inspect the target →
Compound ↔ targetDate not supplied

DAPAGLIFLOZIN

INHIBITOR · CHEMBL3884

A compound–target relationship reported by ChEMBL. It does not establish clinical benefit, safety or an effect on lifespan.

Source: ChEMBL, CC BY-SA 3.0. Selected structured fields; adaptations remain CC BY-SA 3.0. ChEMBL publication: https://europepmc.org/article/MED/30398643 . Licence

Inspect the source record →Inspect the target →
Compound ↔ targetDate not supplied

NYSTATIN

SEQUESTERING AGENT · CHEMBL2364028

A compound–target relationship reported by ChEMBL. It does not establish clinical benefit, safety or an effect on lifespan.

Source: ChEMBL, CC BY-SA 3.0. Selected structured fields; adaptations remain CC BY-SA 3.0. ChEMBL publication: https://europepmc.org/article/MED/30398643 . Licence

Inspect the source record →Inspect the target →
Compound ↔ targetDate not supplied

BUSULFAN

INHIBITOR · CHEMBL2311221

A compound–target relationship reported by ChEMBL. It does not establish clinical benefit, safety or an effect on lifespan.

Source: ChEMBL, CC BY-SA 3.0. Selected structured fields; adaptations remain CC BY-SA 3.0. ChEMBL publication: https://europepmc.org/article/MED/30398643 . Licence

Inspect the source record →Inspect the target →